Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31131009 | 1.00 | AKR1B1 (0.34) | AKR1B1CES2CES1 | |
| SCHEMBL2194521 | 0.87 | MAPT (0.40) | — | |
| SCHEMBL8141334 | 0.80 | — | — | |
| SCHEMBL18879525 | 0.79 | L3MBTL1 (0.42) | — | |
| SCHEMBL26135324 | 0.79 | LTA4H (0.44) | — | |
| SCHEMBL6873077 | 0.78 | — | — | |
| SCHEMBL8093719 | 0.78 | TUBB1 (0.44) | — | |
| SCHEMBL3147462 | 0.78 | MAPT (0.42) | — | |
| SCHEMBL2141511 | 0.76 | — | — | |
| SCHEMBL22118200 | 0.76 | AKR1B1 (0.31) | AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113924-A1 | Neuramindase Inhibitor | NATIONAL INSTITUE OF ADVANCE INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-05-15 | — | — | US | claimed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| EP-4452977-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| EP-4452978-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115150-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115142-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| US-20080113924-A1 | Neuramindase Inhibitor | NATIONAL INSTITUE OF ADVANCE INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | AKR1B1 1932/4885CES2 4038/4885CES1 3324/4885 |
| US-20080113924-A1 | Neuramindase Inhibitor | NMBR, NEU1, NMUR1 | AKR1B1 1222/4885CES2 530/4885CES1 1001/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | AKR1B1 1439/4885CES2 4211/4885CES1 2993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.